pancreatic cancer, biliary tract cancer
Conditions
Interventions
Liver biopsy Tumor biopsy Blood sample collection
Sponsors
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Clinically diagnosed as advanced pancreatobiliary cancer 2) The percutaneous biopsy to intrahepatic tumor was required 3) Age >=20 4) Systemic chemotherapy was planned 5) With written informed consent
Exclusion criteria
Exclusion criteria: 1) History of treatment with corticosteroids(oral intake or intravenously) for chronic inflammatory disease, such as interstitial lung disease, collagen disease, and Crohn disease 2) Treatment with corticosteroids (oral intake or intravenously) for allergic disease within four weeks 3) Surgical treatment within four weeks 4) Paralytic or mechanical bowel obstruction 5) Simultaneous or metachronous double cancers 6) Any other patient whom the physician in charge of the study judges to be unsuitable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum level mRNA expression immunohistochemistry metabolome analysis phsopho-protein analysis cachexia body composition symptoms clinical data | — |
Secondary
| Measure | Time frame |
|---|---|
| the distribution of KRAS mutation | — |
Countries
Japan
Contacts
Public ContactMitsunaga Shuichi
National Cancer Center Hospital East Department of Hepatobiliary and Pancreatic Oncology
Outcome results
None listed